{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014831","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.916126+00:00","generated_at":"2026-05-15T07:55:01.791140+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform","bullets":["Joint development, manufacturing, and licensing agreement signed March 31, 2026.","Combines Oncotelic's proprietary PDAOAI platform with TechForce's robotics hardware.","Platform targets GMP-compliant automated material handling, monitoring, and compliance workflows.","Financial terms not disclosed; revenue sharing and royalties to be negotiated in future agreement.","AI foreground IP owned by Oncotelic; jointly developed IP jointly owned."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014831","json":"https://secwatch.observer/filing/0001493152-26-014831.json","markdown":"https://secwatch.observer/filing/0001493152-26-014831.md","text":"https://secwatch.observer/filing/0001493152-26-014831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:55:01.791140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43f800e0f106f153773fec249f3116f99846180f","claim":"Oncotelic Therapeutics, Inc. entered into Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. valued at Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-253506","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-06-02T20:10:13+00:00","headline":"Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253506","json":"https://secwatch.observer/filing/0001193125-26-253506.json","markdown":"https://secwatch.observer/filing/0001193125-26-253506.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/d95782d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm"}},{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm"}},{"accession":"0001437749-26-018930","ticker":"CPSH","company_name":"CPS TECHNOLOGIES CORP/DE/","filed_at":"2026-06-01T13:35:50+00:00","headline":"CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share","event_type":"other_material","sec_items":["1.01","5.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018930","json":"https://secwatch.observer/filing/0001437749-26-018930.json","markdown":"https://secwatch.observer/filing/0001437749-26-018930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/cpsh20260528_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On May 27, 2026, CPS Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,200,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (“Common Stock”), in a registered direct offering (the “Offering”), at a purchase price of $8.00 per share.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001493152-26-026890","ticker":"XWIN","company_name":"XMax Inc.","filed_at":"2026-06-02T20:30:36+00:00","headline":"XMax raises $3.6M via private placement of 486,500 shares at $7.347/share","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026890","json":"https://secwatch.observer/filing/0001493152-26-026890.json","markdown":"https://secwatch.observer/filing/0001493152-26-026890.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm"}},{"accession":"0001213900-26-064037","ticker":"OSRH","company_name":"OSR Holdings, Inc.","filed_at":"2026-06-02T17:16:53+00:00","headline":"OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-064037","json":"https://secwatch.observer/filing/0001213900-26-064037.json","markdown":"https://secwatch.observer/filing/0001213900-26-064037.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/ea0293037-8k_osrhold.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm"}},{"accession":"0001213900-26-063834","ticker":"VTIX","company_name":"Virtuix Holdings Inc.","filed_at":"2026-06-02T13:15:39+00:00","headline":"Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063834","json":"https://secwatch.observer/filing/0001213900-26-063834.json","markdown":"https://secwatch.observer/filing/0001213900-26-063834.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/ea0292972-8k_virtuix.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/0001493152-26-014831-index.htm","comparable_excerpt":"On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}